Advertisement

Molecular Medicine

, Volume 21, Issue 1, pp 337–345 | Cite as

Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir

  • Jesper F. Højen
  • Thomas A. Rasmussen
  • Karen Lise D. Andersen
  • Anni A. Winckelmann
  • Rune R. Laursen
  • Jesper D. Gunst
  • Holger J. Møller
  • Mayumi Fujita
  • Lars Østergaard
  • Ole S. Søgaard
  • Charles A. Dinarello
  • Martin Tolstrup
Research Article

Abstract

Interleukin-37 (IL-37) is a recently identified cytokine with potent antiinflammatory and immunosuppressive functions. The objective of this study was to compare levels of IL-37 mRNA in immunological subgroups of chronic human immunodeficiency virus-1 (HlV-1)-infected individuals and noninfected controls, to determine IL-37’s association with biomarkers of inflammation and reservoir size. This was a cross-sectional study. The HIV-1-infected patients were categorized in three subgroups depending on their combination antiretroviral therapy (cART) treatment status and CD4+ T-cell count. Quantitative RT-PCR was used for the detection of IL-37 mRNA and HIV-1 DNA in peripheral blood mononuclear cells (PBMCs). Biomarkers in plasma were quantified by enzyme-linked immunosorbent assay (ELISA), whereas T-cell activation was determined by flow cytometry. Lastly, lipopolysaccharide (LPS) stimulations of patients PBMCs were carried out to determine differences in IL-37 mRNA response between the subgroups. Sixty HIV-1-infected patients and 20 noninfected controls were included in the study. Steady-state IL-37 mRNA levels in PBMCs were significantly higher in HIV-1-infected individuals compared with noninfected controls: 2.4-fold (p ≤ 0.01) cART-naïve subjects; 3.9-fold (p ≤ 0.0001) inadequate immunological responders; and 4.0-fold (p ≤ 0.0001) in immunological responders compared with noninfected controls. Additionally, levels of the monocyte inflammatory marker sCD14 correlated with IL-37 mRNA (p = 0.03), whereas there was no association with T-cell activation. Finally, we observed a significant correlation between total viral HIV-1 DNA and IL-37 mRNA in PBMCs (p < 0.0001). Collectively, our data shows that the level of IL-37 mRNA is affected by chronic HIV-1-infection. A relationship with the activation of the monocyte compartment is suggested by the correlation with sCD14 and, interestingly, IL-37 could be related to the size of the total viral HIV-1 reservoir.

Notes

Acknowledgments

We would like to acknowledge all the participating patients who made this study possible. Special gratitude is also extended for Lene Svinth Jøhnke and Erik Hagen for their help and guidance in the lab, and to the medical laboratory assistants in Q-lab. The work was supported by The Danish Research Council (FSS) by grant 0602-02300B to M Tolstrup and by the Augustinusfonden, Familien Hede Nielsens Fund and Ulla og Mogens Folmer Andersens Fund to JF Højen.

Supplementary material

10020_2015_2101337_MOESM1_ESM.pdf (318 kb)
Supplementary material, approximately 318 KB.

References

  1. 1.
    Arend WP. (2002) The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 13:323–40.CrossRefGoogle Scholar
  2. 2.
    Novick D, et al. (1999) Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity. 10:127–36.CrossRefGoogle Scholar
  3. 3.
    Towne JE, et al. (2011) Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity. J Biol. Chem. 286:42594–602.CrossRefGoogle Scholar
  4. 4.
    Dinarello CA, Bufler P. (2013) Interleukin-37. Semin. Immunol. 25:466–8.CrossRefGoogle Scholar
  5. 5.
    Bufler P, Gamboni-Robertson F, Azam T, Kim SH, Dinarello CA. (2004) Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Biochem. J. 381:503–10.CrossRefGoogle Scholar
  6. 6.
    Busfield SJ, et al. (2000) Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics. 66:213–6.CrossRefGoogle Scholar
  7. 7.
    Kumar S, et al. (2002) Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine. 18:61–71.CrossRefGoogle Scholar
  8. 8.
    Pan G, et al. (2001) IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine. 13:1–7.CrossRefGoogle Scholar
  9. 9.
    Smith DE, et al. (2000) Four new members expand the interleukin-1 superfamily. J. Biol. Chem. 275:1169–75.CrossRefGoogle Scholar
  10. 10.
    Taylor SL, Renshaw BR, Garka KE, Smith DE, Sims JE. (2002) Genomic organization of the interleukin-1 locus. Genomics. 79:726–33.CrossRefGoogle Scholar
  11. 11.
    Bufler P, et al. (2002) A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc. Natl. Acad. Sci. U. S. A. 99:13723–8.CrossRefGoogle Scholar
  12. 12.
    Bulau AM, et al. (2014) Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses. Proc. Natl. Acad. Sci. U. S. A. 111:2650–5.CrossRefGoogle Scholar
  13. 13.
    Sharma S, et al. (2008) The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J. Immunol. 180:5477–82.CrossRefGoogle Scholar
  14. 14.
    Luo Y, et al. (2013) IL-37, an inhibitor of innate and adaptive immunity, is elevated in the blood of melanoma patients [abstract]. Pigment Cell Melanoma Res. 26:951.Google Scholar
  15. 15.
    Song L, et al. (2012) Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. J. Clin. Immunol. 33:111–7.CrossRefGoogle Scholar
  16. 16.
    McNamee EN, et al. (2011) Interleukin 37 expression protects mice from colitis. Proc. Natl. Acad. Sci. U. S. A. 108:16711–6.CrossRefGoogle Scholar
  17. 17.
    Nold MF, et al. (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol. 11:1014–22.CrossRefGoogle Scholar
  18. 18.
    Fujita H, Inoue Y, Seto K, Komitsu N, Aihara M. (2012) Interleukin-37 is elevated in subjects with atopic dermatitis. J. Dermatol Sci. 69:173–5.CrossRefGoogle Scholar
  19. 19.
    Moschen AR, et al. (2011) Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol. Med. 17:840–5.CrossRefGoogle Scholar
  20. 20.
    Dinarello CA, Bufler P. (2013) Interleukin-37. Semin. Immunol. 25:466–8.CrossRefGoogle Scholar
  21. 21.
    Luo Y, et al. (2013) IL-37 suppresses contact hypersensitivity by inducing tolerogenic dendritic cells. Cytokine. 63:283.CrossRefGoogle Scholar
  22. 22.
    Hunt PW. (2012) HIV and inflammation: mechanisms and consequences. Curr. HIV/AIDS Rep. 9:139–47.CrossRefGoogle Scholar
  23. 23.
    Neuhaus J, et al. (2010) Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J. Infect. Dis. 201:1788–95.CrossRefGoogle Scholar
  24. 24.
    Kuller LH, et al. (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 5:e203.CrossRefGoogle Scholar
  25. 25.
    Currier JS, et al. (2008) Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 118:e29–35.CrossRefGoogle Scholar
  26. 26.
    Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 370:59–67.CrossRefGoogle Scholar
  27. 27.
    Marin B, et al. (2009) Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS. 23:1743–53.CrossRefGoogle Scholar
  28. 28.
    Deeks SG, Phillips AN. (2009) HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 338:a3172.CrossRefGoogle Scholar
  29. 29.
    Sogaard OS, et al. (2008) Hospitalization for pneumonia among individuals with and without HIV infection, 1995–2007: a Danish population-based, nationwide cohort study. Clin Infect. Dis 47:1345–53.CrossRefGoogle Scholar
  30. 30.
    Brenchley JM, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12:1365–71.CrossRefGoogle Scholar
  31. 31.
    Mavigner M, et al. (2009) HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PloS One. 4:e7658.CrossRefGoogle Scholar
  32. 32.
    Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H. (2008) Residual viraemia in HIV-1-infected patients with plasma viral load ≤ 20 copies/ml is associated with increased blood levels of soluble immune activation markers. Scand. J. Immunol. 68:652–60.CrossRefGoogle Scholar
  33. 33.
    Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD. (2012) Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin. Dev. Immunol. 2012:670957.CrossRefGoogle Scholar
  34. 34.
    Kaufmann GR, et al. (2005) Characteristics, determinants, and clinical relevance of CD4 T cell recovery to < 500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin. Infect. Dis. 41:361–72.CrossRefGoogle Scholar
  35. 35.
    Piketty C, et al. (1998) Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS. 12:745–50.CrossRefGoogle Scholar
  36. 36.
    Piconi S, et al. (2010) Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. AIDS. 24:1991–2000.CrossRefGoogle Scholar
  37. 37.
    Baker JV, et al. (2008) Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J. Acquir. Immune Defic. Syndr. 48:541–6.CrossRefGoogle Scholar
  38. 38.
    Gutierrez F, et al. (2008) Patients’ characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. Curr. HIV Res. 6:100–7.CrossRefGoogle Scholar
  39. 39.
    Nakanjako D, et al. (2011) High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect. Dis. 11:43.CrossRefGoogle Scholar
  40. 40.
    Lederman MM, et al. (2011) Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J. Infect. Dis. 204:1217–26.CrossRefGoogle Scholar
  41. 41.
    Benecke A, Gale M, Jr., Katze MG. (2012) Dynamics of innate immunity are key to chronic immune activation in AIDS. Curr. Opin. HIV AIDS. 7:79–85.CrossRefGoogle Scholar
  42. 42.
    Moller HJ, Hald K, Moestrup SK. (2002) Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scand. J. Clin. Lab. Invest. 62:293–9.CrossRefGoogle Scholar
  43. 43.
    Winckelmann AA, et al. (2013) Administration of a toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. PloS One. 8:e62074.CrossRefGoogle Scholar
  44. 44.
    Ballak DB, et al. (2014) IL-37 protects against obesity-induced inflammation and insulin resistance. Nature Commun. 5:4711.CrossRefGoogle Scholar
  45. 45.
    Llibre JM, et al. (2012) Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir. Ther. 17:355–64.CrossRefGoogle Scholar
  46. 46.
    Brenchley JM, Price DA, Douek DC. (2006) HIV disease: fallout from a mucosal catastrophe? Nat. Immunol. 7:235–9.CrossRefGoogle Scholar
  47. 47.
    Marchetti G, Tincati C, Silvestri G. (2013) Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin. Microbiol. Rev. 26:2–18.CrossRefGoogle Scholar
  48. 48.
    van de Veerdonk FL, et al. (2014) Protective host defense against disseminated candidiasis is impaired in mice expressing human interleukin-37. Front. Microbiol. 5:762.PubMedGoogle Scholar
  49. 49.
    Wiercinska-Drapalo A, Flisiak R, Jaroszewicz J, Prokopowicz D. (2004) Increased plasma transforming growth factor-beta1 is associated with disease progression in HIV-1-infected patients. Viral Immunol. 17:109–13.CrossRefGoogle Scholar
  50. 50.
    Garba ML, Pilcher CD, Bingham AL, Eron J, Frelinger JA. (2002) HIV antigens can induce TGF-beta(1)-producing immunoregulatory CD8+ T cells. J. Immunol. 168:2247–54.CrossRefGoogle Scholar
  51. 51.
    Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. (2012) Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J. Infect. Dis. 206:1558–67.CrossRefGoogle Scholar
  52. 52.
    Sandler NG, et al. (2011) Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 203:780–90.CrossRefGoogle Scholar
  53. 53.
    Lien E, et al. (1998) Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood. 92:2084–92.PubMedGoogle Scholar
  54. 54.
    Dinarello CA. (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27:519–50.CrossRefGoogle Scholar
  55. 55.
    Dinarello CA. (2010) Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev. 29:317–29.CrossRefGoogle Scholar
  56. 56.
    Zeng Q, et al. (2012) Therapeutic potential of interleukin-37 for suppression of aortic valve inflammatory and osteogenic responses. Circulation. 126:A11803.CrossRefGoogle Scholar
  57. 57.
    Cassol E, et al. (2010) Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J. Infect. Dis. 202:723–33.CrossRefGoogle Scholar
  58. 58.
    Burdo TH, et al. (2011) Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J. Infect. Dis. 204:154–63.CrossRefGoogle Scholar
  59. 59.
    Moller HJ. (2012) Soluble CD163. Scand. J. Clin. Lab. Invest. 72:1–13.CrossRefGoogle Scholar
  60. 60.
    Hatano H, et al. (2013) Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J. Infect. Dis. 208:50–6.CrossRefGoogle Scholar
  61. 61.
    Poizot-Martin I, et al. (2013) Lack of correlation between the size of HIV proviral DNA reservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years. J. Clin. Virol. 57:351–5.CrossRefGoogle Scholar
  62. 62.
    Marchetti G, et al. (2010) Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART. AIDS. 24:1455–60.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Jesper F. Højen
    • 1
  • Thomas A. Rasmussen
    • 1
  • Karen Lise D. Andersen
    • 1
  • Anni A. Winckelmann
    • 1
  • Rune R. Laursen
    • 1
  • Jesper D. Gunst
    • 1
  • Holger J. Møller
    • 2
  • Mayumi Fujita
    • 3
  • Lars Østergaard
    • 1
  • Ole S. Søgaard
    • 1
  • Charles A. Dinarello
    • 4
    • 5
  • Martin Tolstrup
    • 1
  1. 1.Department of Infectious DiseasesAarhus University HospitalAarhus NDenmark
  2. 2.Department of Clinical BiochemistryAarhus University HospitalAarhusDenmark
  3. 3.Department of DermatologyUniversity of Colorado DenverAuroraUSA
  4. 4.Division of Infectious DiseasesUniversity of Colorado DenverAuroraUSA
  5. 5.Department of MedicineRadboud University Medical CentreNijmegenThe Netherlands

Personalised recommendations